Discontinuation of medication due to adverse events · people with chronic hepatitis C
Peginterferon plus ribavirin showed no clear difference in adverse events leading to treatment discontinuation compared with non‐pegylated interferon plus ribavirin (low certainty).
1 finding from 1 review
Sustained virological response · people with chronic hepatitis C
It is very uncertain whether peginterferon plus ribavirin changes sustained virological response compared with non‐pegylated interferon plus ribavirin (very low certainty).
1 finding from 1 review
Overall survival ‐ not reported · children and adolescents (< 18 years of age) with first‐line ALL
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in event‐free survival compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in hypersensitivity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower pancreatitis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in thromboembolism compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… showed no clear difference in osteonecrosis compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (low certainty).
1 finding from 1 review
Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL
Summary of findings table ‐ Intermittent PEG‐asparaginase treatment… probably leads to lower asparaginase‐associated toxicity compared with continuous PEG‐asparaginase treatment (15 doses, 1000 IU/m2, IM) (moderate certainty).
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).
1 finding from 1 review
Faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes faecal incontinence compared with low dose PEG (very low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Death · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to lower relapse(recurrence after stopping) compared with pegylated interferon alone (low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in end‐of‐treatment response compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Sustained virological response · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to higher sustained virological response compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Treatment discontinuation · patients on HD with HCV infection
Pegylated interferon plus ribavirin showed no clear difference in treatment discontinuation compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Adverse events · patients on HD with HCV infection
Pegylated interferon plus ribavirin may leads to higher adverse events compared with pegylated interferon alone (low certainty).
1 finding from 1 review
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate